Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
This study has been completed.
Study NCT01021358   Information provided by Abbott

First Received on November 25, 2009.   Last Updated on December 16, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Chronic Lymphocytic Leukemia
Solid Tumors
Additional conditions recognized in this trial
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
ABT-263
Ketoconazole
More general drug interventions related to this trial
14-alpha Demethylase Inhibitors
Anti-Infective Agents
Antifungal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services